Dang Shen for Health & Longevity

Evidence Review created on 10/18/2026 using AI4L + evidence-mcp / Gemini 4 Argon

Also known as: Codonopsis pilosula, Codonopsis pilosula var. modesta, Codonopsis tangshen, Codonopsis, Codonopsis Radix, Radix Codonopsis, Dangshen, Poor Man’s Ginseng, Bonnet Bellflower, Bastard Ginseng, Chuan Dang Shen, Lu Dang Shen, Wen Dang Shen, Baitiao Dang Shen, Campanumoea pilosula

Motivation

Dang Shen (Codonopsis pilosula, Codonopsis pilosula var. modesta, and Codonopsis tangshen, also known as Poor Man’s Ginseng) is a perennial root herb in the bellflower family used across East Asia as both a daily culinary tonic and a botanical medicine. Its active plant sugars and aromatic root compounds influence cellular energy sensing, antioxidant defense pathways, and gut-immune signaling. Proactive adults interested in longevity consider Dang Shen as a gentler, non-stimulating alternative to Panax ginseng for supporting respiratory function, immune resilience, and cognitive health.

For nearly three centuries, classical Chinese medical texts have paired or substituted Dang Shen with costlier roots as a daily restorative tonic. Modern clinical trials have investigated multi-herb oral root brews and intravenous co-extracts containing Dang Shen for lung function and immune recovery, while laboratory studies have tested isolated root fractions on cellular aging and brain health models.

This review examines the clinical and laboratory evidence for Dang Shen in health and longevity, evaluating how much of the human data derives from multi-herb combinations versus standalone oral use, alongside its absorption and clearance, drug interactions, quality-control hazards, and practical dosing protocols.

Benefits - Risks - Protocol - Conclusion

This section curates four peer-reviewed narrative reviews that provide a comprehensive overview of Dang Shen’s phytochemistry, molecular pharmacology, immunomodulatory polysaccharides, and traditional toxicology.

Details how extraction methods and molecular weight distributions govern the mucosal, macrophage, and lymphocyte signaling activities of Codonopsis pilosula polysaccharides (CPPs, complex carbohydrate polymers isolated from the root).

Catalogs over 200 isolated constituents, including alkaloids, polyacetylenes, phenylpropanoids, and triterpenoids, and maps their neuroprotective, metabolic, and anti-inflammatory mechanisms.

Examines the chemistry, biosynthesis, and glutamine-metabolism-targeting mechanisms of lobetyolin, the primary polyacetylene glycoside marker used to standardize Dang Shen extracts.

Provides a foundational ethnopharmacological comparison of 40 Codonopsis species, linking classical Chinese medical applications with modern preclinical toxicology and bioactivity data.

No articles or episodes on Dang Shen were found from priority experts Rhonda Patrick, Peter Attia, Andrew Huberman, Life Extension Magazine, or Lifespan.io, and Chris Kresser mentions Codonopsis only once in a bare herb list; only four qualifying narrative reviews are listed to avoid padding with systematic reviews or overlapping sources.

Grokipedia

No dedicated article for Dang Shen (Codonopsis pilosula) is available on Grokipedia.

Examine

Summarizes Codonopsis pilosula (Dangshen) as a traditional, lower-cost replacement for Panax ginseng with potential cognitive-supporting properties, while noting that human clinical research remains sparse and its detailed research breakdown is currently archived.

ConsumerLab

No dedicated article or product review for Dang Shen (Codonopsis pilosula) is available on ConsumerLab.

Systematic Reviews

This section lists five systematic reviews and meta-analyses (statistical analyses combining results from multiple independent studies) evaluating clinical trials of herbal formulations containing Dang Shen.

Identifies Codonopsis pilosula among the core botanical ingredients associated with lower chronic chemotherapy-induced peripheral nerve toxicity in colorectal cancer patients.

Pools 44 randomized controlled trials (RCTs, clinical studies randomly assigning participants to groups) of Livzon Pharmaceutical’s injection showing improved tumor response and reduced toxicity.

Synthesizes 40 RCTs (3,029 patients) and identifies Codonopsis via sensitivity analysis as a primary contributor to improved objective tumor response rates.

Analyzes 32 RCTs (2,224 patients) showing that formulas containing Codonopsis reduce severe chemotherapy-induced neutropenia (abnormally low neutrophil white blood cell counts).

Evaluates 48 RCTs demonstrating improved lung function, six-minute walk distance (6MWD, distance walked in six minutes), and quality of life without excess adverse events.

While these meta-analyses assess both efficacy and adverse events in multi-herb regimens, no systematic review covers standalone Dang Shen monotherapy or its isolated risks.

Mechanism of Action

Dang Shen acts through two chemical classes: macromolecular CPPs (inulin-type fructans and pectic heteropolysaccharides) and small molecules, including polyacetylenes (lobetyolin), phenylpropanoids (syringin, tangshenoside I), sesquiterpene lactones (atractylenolide III), and alkaloids (codonopsine). In neuronal aging models, CPPs preserve nicotinamide adenine dinucleotide (NAD+, a coenzyme essential for cellular energy and repair) by downregulating cluster of differentiation 38 (CD38, the primary NAD+-degrading enzyme), which activates sirtuin 1 (SIRT1) and sirtuin 3 (SIRT3, NAD+-dependent deacetylase enzymes regulating mitochondrial function). CPPs and luteolin also activate forkhead box O (FOXO, stress-resistance transcription factors) and nuclear factor erythroid 2-related factor 2 (Nrf2, a master antioxidant regulator) while inhibiting Toll-like receptor 4 (TLR4, an innate immune receptor) and nuclear factor kappa B (NF-κB, a pro-inflammatory transcription factor; a 2025 CPP review). In Alzheimer’s disease (AD, progressive neurodegenerative dementia) models, CPPs and lobetyolin inhibit beta-site amyloid precursor protein cleaving enzyme 1 (BACE1, the amyloid-producing enzyme) and activate protein phosphatase 2A (PP2A, a tau-dephosphorylating enzyme). Competing mechanisms exist: root nor-sesquiterpenoids (pilosulinene A) inhibit SIRT1 in vitro (a 2024 Codonopsis review), and root extracts upregulate androgen receptor (AR, a hormone receptor driving prostate growth) via phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt, a cell-survival signaling cascade) in prostate tumors. Pharmacokinetically, oral fructans show low bioavailability, broad gastrointestinal, hepatic, and renal distribution, and a long elimination half-life ($t_{1/2}$, time for plasma concentration to halve), whereas small molecules undergo rapid absorption, cytochrome P450 (CYP450, liver drug-metabolizing enzymes) clearance, and in vitro cytochrome P450 3A4 (CYP3A4, the main human drug-clearing enzyme) inhibition.

Historical Context & Evolution

Imperial Chinese physicians historically prized wild ginseng (Panax ginseng) from the Shangdang region of Shanxi province (Shangdang Renshen). By the late Ming and early Qing dynasties, overharvesting drove native Shangdang Panax ginseng to local extinction. Practitioners substituted the sweet roots of bellflower vines (Codonopsis species) from the same mountains, naming them Dang Shen (“ginseng of Shangdang”). In 1757, Qing physician Wu Yiluo formally distinguished Dang Shen in his materia medica Ben Cao Cong Xin, defining its original intended use in traditional Chinese medicine (TCM, China’s classical medical system) as a gentle tonic for replenishing spleen and lung qi (vital energy), generating fluids, and relieving fatigue without the overstimulating effects attributed to Panax ginseng (Gao et al., 2018 review).

Interest in Dang Shen for health optimization expanded after China’s National Health Commission designated Codonopsis pilosula a dual medicine-and-food substance (a 2025 review), prompting isolation of its polysaccharides and glycosides. Twentieth-century and early clinical studies stimulated erythropoiesis (red blood cell production; a 2018 review), improved high-altitude hypoxia tolerance at 5,200 meters, and restored T-lymphocytes during chemotherapy (a 2017 meta-analysis). Clinical trials later tested chronic obstructive pulmonary disease (COPD, progressive airflow-limiting lung disease; a 48-RCT meta-analysis) and diabetic sarcopenia (age- and diabetes-related loss of muscle mass and strength), whereas a manufacturer-co-authored 2025 IPF RCT (idiopathic pulmonary fibrosis, progressive lung scarring) preserved total lung capacity (TLC, total lung air volume) without improving forced vital capacity (FVC, maximum air exhaled forcefully), showing that multi-herb outcomes depend on disease pathology.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: published human RCTs and meta-analyses have evaluated Dang Shen only within multi-herb formulations or intravenous co-extracts rather than as standalone oral monotherapy.

Medium 🟩 🟩

No benefit reaches Medium: no single human RCT or comparative observational cohort study has tested standalone oral Codonopsis pilosula, Codonopsis pilosula var. modesta, or Codonopsis tangshen without co-administered botanicals.

Low 🟩

Respiratory Function and Exercise Tolerance ⚠️ Conflicted

A meta-analysis of 48 COPD RCTs and an altitude RCT improved forced expiratory volume in one second (FEV1, first-second exhaled volume) and 6MWD. Conversely, a 26-week IPF RCT of 12-herb Jinbei liquid preserved TLC without improving FVC or symptom scores. Evidence is indirect (multi-herb formulas) and favors COPD over IPF.

Magnitude: In COPD, multi-herb Dang Shen formulae plus pharmacotherapy increased FEV1 by mean difference (MD, average difference between groups) 0.22 L across the 95% confidence interval (CI, range containing the true value with 95% probability; 0.13 to 0.31), 6MWD by MD 51.43 m (95% CI 30.06 to 72.80), and reduced St George’s Respiratory Questionnaire (SGRQ, a 0–100 respiratory impact scale where lower is better) scores by MD -9.05 points (95% CI -12.72 to -5.38) versus pharmacotherapy alone (and MD -7.19, 95% CI -10.82 to -3.56 versus placebo); in IPF, Jinbei oral liquid preserved TLC (+136 mL versus -523 mL with placebo; difference 659 mL, 95% CI -1215 to -104, $p = 0.02$, where $p$ is the probability of a chance finding, though least-squares mean difference was 307 mL, 95% CI -759 to 146, $p = 0.18$) but did not significantly alter FVC% predicted (difference 2.10%, 95% CI -7.13 to 2.93, $p = 0.41$) or FVC (-67 mL, 95% CI -238 to 104, $p = 0.44$).

Muscle Mass, Strength, and Glycemic Control in Sarcopenia ⚠️ Conflicted

In a 12-week RCT of 90 older adults with diabetic sarcopenia, eight-herb Shenqi paste improved muscle mass, grip strength, chair-stand speed, fasting blood glucose (FBG, overnight fasting blood sugar), and C-reactive protein (CRP, inflammation marker). However, glycated hemoglobin (HbA1c, three-month average glucose) was unchanged. Evidence is indirect (co-formulation).

Magnitude: Statistically significant group-by-time improvements in skeletal muscle mass index ($p < 0.001$), handgrip strength ($p < 0.001$), five-time chair stand test duration ($p < 0.001$), CRP ($p < 0.001$), and FBG ($p = 0.018$) versus placebo paste over 12 weeks, with no significant between-group difference in HbA1c ($p > 0.05$); exact between-group numerical score differences were not reported in the abstract.

Memory Acquisition and Retention in Healthy Adults

In a double-blind RCT of 60 healthy adults, twice-daily oral dosing with 75 mg Codonopsis pilosula glycosides plus 40 mg Ginkgo biloba extract improved memory acquisition, retention, and health scores versus placebo and Ginkgo alone via cholinergic and BACE1 modulation. Evidence is indirect (co-administered with Ginkgo biloba).

Magnitude: Statistically significant improvements in computerized memory acquisition, retention, and Short Form-12 (SF-12, a standardized 12-item health status questionnaire) scores versus placebo and Ginkgo biloba monotherapy; exact numerical score differences were not reported in the study abstract.

Endothelial Function, Vascular Inflammation, and Lipid Peroxidation

In a 6-week RCT of 80 prehypertensive adults stratified by baseline systolic blood pressure (SBP, peak arterial pressure), oral Codonopsis lanceolata extract significantly lowered high-sensitivity C-reactive protein (hs-CRP, vascular inflammation marker) and malondialdehyde (MDA, lipid peroxidation marker) while raising serum nitrite versus placebo. Evidence is indirect (congener species Codonopsis lanceolata).

Magnitude: Statistically significant between-group increase in serum nitrite ($p = 0.038$ in the elevated SBP subgroup, 120–129 mmHg) and between-group reductions in hs-CRP ($p = 0.020$) and MDA ($p = 0.039$ in the stage 1 hypertension subgroup, SBP 130–139 mmHg) versus starch placebo over 6 weeks; the study abstract reports no numerical outcome figures.

Chemotherapy-Induced Cytopenia, Neuropathy, and Immune Suppression ⭕️ Not Central to Longevity

Meta-analyses in lung cancer, immunity, gastric cancer, neutropenia, and neuropathy (nerve damage) show that intravenous Shenqi Fuzheng Injection (SFI, a 1:1 Codonopsis and Astragalus co-extract) or decoctions raise T-cells and natural killer (NK, cytotoxic immune) cells while reducing cytopenia (blood-cell deficiency). Targets oncology care (indirect co-formulations).

Magnitude: SFI plus platinum chemotherapy increased objective tumor response by risk ratio (RR, ratio of event probability in treated versus control groups) 1.27 (95% CI 1.18 to 1.37) and quality-of-life status by RR 1.41 (95% CI 1.31 to 1.52), while reducing grade 3/4 leukopenia (low white blood cells; RR 0.61, 95% CI 0.53 to 0.71), thrombocytopenia (low platelets; RR 0.62, 95% CI 0.55 to 0.70), severe neutropenia (RR 0.45, 95% CI 0.31 to 0.65), and chronic nerve toxicity (RR 0.66, 95% CI 0.56 to 0.78) versus chemotherapy alone.

Cardiac Function in Heart Failure ⭕️ Not Central to Longevity

A meta-analysis of 21 RCTs in chronic heart failure found that adding intravenous SFI to standard therapy increased left ventricular ejection fraction (LVEF, blood fraction pumped per beat), stroke volume, and cardiac output while lowering brain natriuretic peptide (BNP, cardiac wall-stress hormone). This targets heart failure (indirect intravenous co-extract).

Magnitude: Clinical effectiveness odds ratio (OR, ratio of odds of an event in treated versus control groups) 3.91 (95% CI 2.63 to 5.83), LVEF MD +0.08 (95% CI 0.05 to 0.12), stroke volume MD +9.42 mL (95% CI 6.61 to 12.22), cardiac output MD +0.98 L/min (95% CI 0.61 to 1.36), and BNP MD -139.05 pg/mL (95% CI -211.08 to -67.02) versus conventional therapy alone.

Speculative 🟨

Lifespan Extension and Locomotor Healthspan in Model Organisms

In Caenorhabditis elegans, isolated luteolin and glycitein preserve age-related locomotion and muscle mitochondria via FOXO signaling, while pectic polysaccharides lower reactive oxygen species (ROS, damaging oxygen radicals). No human longevity studies exist.

Attenuation of Amyloid-Beta and Tau Neuropathology

In transgenic AD mice, intragastric CPPs inhibit hippocampal BACE1 and restore PP2A-mediated tau dephosphorylation, rescuing synaptic plasticity and spatial memory. Evidence is restricted to rodent and neuronal cell models.

Gut Microbiome Remodeling and Neuroinflammation Suppression

In accelerated-aging mice, oral CPPs repair intestinal tight junctions and raise microbial 3-indole-glyoxylic acid, inhibiting microglial Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3, inflammatory cytokine pathway) signaling. Human data are lacking.

Mitigation of Cellular Senescence in Aging Lung and Myocardium

In aged mice, Codonopsis tangshen extract reduces lung senescence and fibrosis via telomere-protective and heat-shock pathways. Root polysaccharides also attenuate chemotherapy-induced myocardial senescence in rodents, without human confirmation.

Restoration of T-Cell Immunity in Senescent Mice

In senescence-accelerated mice, a Codonopsis pilosula pectic polysaccharide stimulates lymphocyte proliferation and expands helper and cytotoxic T-cell subsets while upregulating antiviral cytokines. These findings remain preclinical.

Benefit-Modifying Factors

  • Genetic polymorphisms: No human pharmacogenomic trials have mapped genetic modifiers of Dang Shen efficacy, though functional variants in CYP3A4 or SIRT1 could theoretically alter small-molecule clearance or downstream deacetylase signaling based on in vitro CYP3A4 metabolism and sirtuin modulation.
  • Baseline biomarker levels: In a prehypertensive RCT of Codonopsis lanceolata, significant reductions in hs-CRP and MDA occurred primarily in participants with stage 1 hypertension (SBP 130–139 mmHg) rather than lower-baseline prehypertension, indicating greater benefit when baseline vascular inflammation and blood pressure are elevated.
  • Sex-based differences: In rat pharmacokinetic studies, females showed 3-fold higher intestinal permeability ($10 \times 10^{-6}$ vs. $3.3 \times 10^{-6}\text{ cm/s}$) and slower clearance of atractylenolide III, yielding higher area under the curve (AUC, total drug exposure) and maximum plasma concentration ($C_{\max}$, peak blood level).
  • Pre-existing health conditions: Stronger functional responses occur in baseline airflow obstruction (a COPD meta-analysis), chemotherapy-induced immunosuppression (an oncology meta-analysis), or diabetic sarcopenia, whereas patients with established idiopathic pulmonary fibrosis derived no spirometric benefit from a Dang Shen formula.
  • Age-related considerations: Older adults with age-related declines in skeletal muscle mass, T-cell repertoire, and cellular NAD+ homeostasis (driven by age-associated CD38 upregulation) represent the primary biological population in which Dang Shen’s immunomodulatory and metabolic effects are most pronounced.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: human RCTs and post-marketing cohorts have evaluated Dang Shen only within multi-herb formulations or intravenous co-extracts rather than as standalone oral monotherapy.

Medium 🟥 🟥

No risk reaches Medium: no single human RCT, cohort study, or pharmacovigilance series has isolated an adverse event attributable to standalone oral Codonopsis pilosula, Codonopsis pilosula var. modesta, or Codonopsis tangshen.

Low 🟥

Mild Gastrointestinal Upset, Dry Mouth, and Insomnia ⚠️ Conflicted

In a meta-analysis of 48 COPD RCTs and a sarcopenia RCT of multi-herb Dang Shen formulas, occasional gastrointestinal upset, dry mouth, insomnia, and dizziness occurred. However, event rates were balanced across groups, and an oncology meta-analysis showed reduced chemotherapy gastrointestinal toxicity. Evidence is indirect (co-formulations) and indicates minimal risk.

Magnitude: Across 48 COPD trials, mild adverse events (gastrointestinal upset, dry mouth, and insomnia) were rare and balanced between Dang Shen herbal formula and control arms; in advanced lung cancer (a meta-analysis of 44 RCTs in 3,475 patients), SFI significantly reduced chemotherapy-induced nausea and vomiting (RR 0.63, 95% CI 0.52 to 0.77) and diarrhea (RR 0.48, 95% CI 0.37 to 0.64) versus chemotherapy alone.

Respiratory and Hepatobiliary Adverse Events in Pulmonary Fibrosis ⚠️ Conflicted

In a 26-week double-blind IPF RCT, oral Jinbei liquid (a 12-herb Codonopsis pilosula decoction) plus Corbrin capsules yielded numerically higher rates of cough, pneumonia, and abnormal liver function than placebo. However, between-group differences were not statistically significant. Evidence is indirect (12-herb co-formulation) and indicates no confirmed excess risk.

Magnitude: Treatment-emergent adverse events (including cough, pneumonia, and abnormal liver function, each occurring in $> 5\%$ of participants) occurred in 55.9% (19/34) of the Jinbei oral liquid group versus 32.4% (11/34) of the placebo group, and serious adverse events occurred in 14.7% (5/34) versus 11.8% (4/34), with no statistically significant difference between groups ($p > 0.05$).

Parenteral Infusion and Hypersensitivity Reactions

In a post-marketing safety review of intravenous SFI covering 20,100 monitored hospital patients and 16 published case reports, rare case-report reactions included rash, chills, palpitations, shortness of breath, superficial phlebitis (vein inflammation), and isolated thrombocytopenia. These stem from intravenous delivery and excipients. Evidence is indirect (intravenous co-extract with Astragalus).

Magnitude: Adverse drug reaction incidence of 1.85 per 1,000 patients among 20,100 monitored hospitalized patients, and 23 cases among 8,484 intensively monitored patients (no control group), with no renal toxicity observed even at above-standard dosing courses.

Speculative 🟨

Antagonism of Androgen-Deprivation Therapy in Prostate Cancer

In prostate cancer xenograft mice and rats, oral Codonopsis Radix upregulated tumor AR expression via PI3K/Akt and lowered abiraterone bioavailability. This promoted tumor growth and blunted abiraterone efficacy in rodents.

Cytochrome P450 3A4 Inhibition

In human microsomal assays, Codonopsis tangshen extracts inhibited CYP3A4 activity with half-maximal inhibitory concentrations ($\text{IC}_{50}$, concentration inhibiting 50% of enzyme activity) of 17–83 µg/mL. Clinical human interaction trials are lacking.

Platelet Inhibition and Prolonged Coagulation Time

In rats, Codonopsis clematidea inhibited platelet signaling, prolonging prothrombin time (PT, extrinsic clotting time), activated partial thromboplastin time (aPTT, intrinsic clotting time), and international normalized ratio (INR, clotting ratio). Human data are lacking.

Appetite and Weight Suppression from Sulfur-Fumigated Roots

Postharvest sulfur dioxide ($\text{SO}_2$) bleaching depletes lobetyolin and generates 15 synthetic organosulfur compounds. In mice, sulfur-fumigated root extract suppressed appetite and weight gain versus vacuum-packed roots.

Exposure to Pesticide Residues, Cadmium, and Botanical Adulterants

Market testing of 164 Chinese batches found 20 pesticides in 23.78% of samples that leach into decoctions. Roots also accumulate soil cadmium (hydroponic study) and suffer Stellariae Radix adulteration.

Risk-Modifying Factors

Key Interactions & Contraindications

  • Androgen receptor antagonists and steroidogenesis inhibitors (hormone-synthesis-blocking drugs such as abiraterone acetate, enzalutamide, apalutamide): Avoid (theoretical, supported by rodent data). Codonopsis Radix lowers abiraterone bioavailability and upregulates tumor AR expression via PI3K/Akt, counteracting antitumor efficacy; protocols exclude it during androgen-deprivation therapy.
  • Narrow-therapeutic-index CYP3A4 substrates (cyclosporine, tacrolimus, midazolam, simvastatin, irinotecan): Caution warranted (theoretical, based on in vitro human CYP3A4 inhibition, $\text{IC}_{50}$ 17–83 µg/mL). Co-administration may elevate plasma drug concentrations and toxicity; clinical management typically separates oral dosing by 3–4 hours and tracks therapeutic drug troughs.
  • Prescription anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel): Caution warranted (theoretical, based on rodent platelet inhibition and prolonged PT/aPTT/INR). Concurrent use may additively impair hemostasis and increase bleeding risk; clinical monitoring checks PT/INR within 7–14 days of starting or stopping Dang Shen.
  • Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs, pain and inflammation medications such as aspirin, ibuprofen, naproxen): Caution warranted (theoretical, inferred from antiplatelet thromboxane and receptor suppression). Daily co-administration with aspirin or NSAIDs may increase mucosal or surgical bleeding tendency, particularly with high-dose antiplatelet regimens.
  • Anticoagulant or antiplatelet supplements (Ginkgo biloba, Salvia miltiorrhiza, garlic, marine omega-3 fatty acids): Monitoring warranted (theoretical). Although 75 mg Codonopsis glycosides plus 40 mg Ginkgo biloba was well tolerated in healthy adults, stacking antiplatelet botanicals may prolong bleeding time and increase easy bruising.
  • Blood-pressure- or glucose-lowering supplements and drugs (losartan, amlodipine, metformin, berberine, Astragalus membranaceus): Monitoring warranted. Codonopsis formulations potentiate reductions in SBP and FBG, which can be therapeutically additive or cause mild symptomatic hypotension or hypoglycemia during initiation.
  • Scheduled surgical procedures and general anesthesia: Preoperative washout indicated (theoretical, standard clinical monograph precaution supported by coagulation prolongation in rodents). Standard surgical protocols pause all Dang Shen products at least 14 days before elective surgery to prevent perioperative bleeding or anesthetic CYP3A4 interactions.

Populations who should avoid Dang Shen:

  • Men with prostate cancer or prostatic intraepithelial neoplasia, particularly those treated with abiraterone acetate or AR antagonists (Zhang et al., 2021).
  • Pregnant or lactating women, excluded across clinical trials due to unestablished fetal and neonatal safety (NCT05613465, NCT06375824).
  • Individuals with severe hepatic or renal impairment, defined in clinical trial exclusion criteria as ALT or AST $> 2.5\times$ upper limit of normal (ULN, top of the laboratory reference range) or serum creatinine $> 1.5\times$ ULN (NCT03455205).
  • Individuals with uncontrolled hypertension, defined as SBP $> 160\text{ mmHg}$ or diastolic blood pressure (DBP, arterial pressure between heartbeats) $> 100\text{ mmHg}$, New York Heart Association (NYHA, heart-failure severity scale) Class III–IV heart failure (NCT03455205), hypotension (SBP $< 80\text{ mmHg}$), or active bleeding (NCT05631782).
  • Patients with severe thrombocytopenia (platelets $< 75 \times 10^9\text{/L}$) or active interstitial lung disease, excluded in oncology trials (NCT07843251) and showing numerically higher respiratory and hepatic adverse events in IPF (Zhang et al., 2025).

Risk Mitigation Strategies

Doses, timings, and monitoring intervals below follow common clinical practice unless cited.

Therapeutic Protocol

Timing, splitting, and titration parameters below follow common practice unless cited.

Discontinuation & Cycling

  • Treatment duration (short-term versus lifelong): Clinical trials evaluate continuous courses of 6 weeks to 26 weeks, while traditional East Asian dietary practice uses Dang Shen intermittently in seasonal soups rather than as an uninterrupted lifelong daily pharmaceutical.
  • Withdrawal effects: No physiological dependence, rebound fatigue, or withdrawal syndrome has been reported following abrupt cessation of Dang Shen in a systematic review of clinical trials or 90-day toxicological studies.
  • Tapering protocol: No dose taper is required when stopping Dang Shen; however, individuals using it alongside antihypertensive or hypoglycemic agents typically track blood pressure and FBG for 1–2 weeks after cessation in case additive metabolic effects recede.
  • Cycling schedule for maintaining efficacy: To prevent TLR4/NF-κB receptor desensitization (a 2025 CPP review) and limit trace agrochemical exposure (Wang et al., 2022), protocols typically cycle 8–12 weeks on followed by 2–4 weeks off, or 5 days weekly (NCT06375824).

Sourcing and Quality

  • Botanical species authentication: The Chinese Pharmacopoeia recognizes Codonopsis pilosula, Codonopsis pilosula var. modesta, and Codonopsis tangshen (Bai et al., 2025 review). Genetic barcoding or liquid-chromatography fingerprinting prevents commercial adulteration with Stellariae Radix.
  • Postharvest processing and sulfur-free certification: Authentic roots feature a “lion’s head” crown and “chrysanthemum heart” cross-section (Liang et al., 2024 review). Bleached whitish-yellow roots treated with $\text{SO}_2$ suffer lobetyolin loss and 15 sulfur byproducts, making low-temperature vacuum-packed roots preferable.
  • Formulation and chemical standardization: Water decoctions and aqueous extracts capture high-molecular-weight CPPs (Pan et al., 2025 review), whereas hydroethanolic extracts concentrate lipophilic lobetyolin and atractylenolide III (Mu et al., 2025). Dual-extracted powders standardized to $\ge 20\%$ polysaccharides and $\ge 0.05\%$ lobetyolin preserve both fractions.
  • Contaminant testing and reputable suppliers: Mass-spectrometry batch testing screens for cadmium, lead, and 20+ agricultural pesticides. Reputable suppliers offering Good Manufacturing Practice (GMP, regulatory manufacturing quality standard)-certified unsulfured granules or roots include Treasure of the East, Kaiser Pharmaceutical, Mayway (Plum Flower), and Nammex.

Practical Considerations

  • Time to effect: Acute improvements in high-altitude symptom scores and ventilatory function appear within 5–10 days, vascular and antioxidant changes (hs-CRP, MDA, nitrite) emerge by 6 weeks, and gains in muscle mass and strength or COPD spirometry (a 48-RCT meta-analysis) require 12–24 weeks.
  • Common pitfalls: Consumers frequently confuse Dang Shen (Codonopsis pilosula, a sweet qi-tonifying bellflower root) with Dan Shen (Salvia miltiorrhiza, bitter red sage root used as a potent cardiovascular anticoagulant), or purchase cheap sulfur-fumigated culinary roots whose chemical profile is degraded.
  • Regulatory status: China regulates Codonopsis pilosula as a Pharmacopoeia drug and dual-use food-medicine substance (Bai et al., 2025 review), while SFI is a prescription injection (Ai et al., 2014 review). Western markets sell oral forms as dietary supplements (Gao et al., 2018 review).
  • Cost and accessibility: Dried unsulfured Codonopsis pilosula root and concentrated granules are widely accessible and inexpensive, typically costing $10–$25 per month at standard 9–15 g/day doses, roughly one-fifth the cost of aged Panax ginseng.

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Before initiating Dang Shen supplementation, baseline assessment typically includes a laboratory panel comprising FBG, hs-CRP, complete blood count (CBC, automated measurement of red cells, white cells, and platelets) with differential, hepatic transaminases (ALT and AST), coagulation parameters (PT and INR, particularly when combined with antiplatelet or anticoagulant agents), and total PSA in men over 40 years of age, alongside seated morning blood pressure and handgrip dynamometry. Ongoing clinical monitoring typically repeats safety blood tests (ALT, AST, CBC, and PT/INR) at 4 weeks after initiation, and re-evaluates all efficacy and safety biomarkers at 12 weeks and every 6 months thereafter during cyclical supplementation.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting Blood Pressure (SBP / DBP) No established target; track change from individual baseline Expected to change (efficacy) & safety check Prehypertension trial subgroup was SBP $120\text{–}139\text{ mmHg}$ or DBP $80\text{–}89\text{ mmHg}$ (Shin et al., 2020); measured seated in the morning after 5 minutes of rest.
High-Sensitivity C-Reactive Protein (hs-CRP) $0.0\text{–}3.0\text{ mg/L}$ (standard reference range) Expected to change (efficacy) Reduced in stage 1 hypertension (Shin et al., 2020) and sarcopenia (Hua et al., 2026); drawn fasting in the absence of acute infection.
Fasting Blood Glucose (FBG) $70\text{–}99\text{ mg/dL}$ (standard reference range) Expected to change (efficacy) Decreased in older adults with diabetic sarcopenia (Hua et al., 2026); 8–12 hour overnight fast required.
Complete Blood Count (CBC) with Differential WBC $4.5\text{–}11.0 \times 10^9\text{/L}$; Platelets $150\text{–}400 \times 10^9\text{/L}$ (standard reference range) Expected to change (efficacy) & safety check WBC stands for white blood cell count; tracks leukocyte/lymphocyte support (Chen et al., 2016 meta-analysis) and screens for rare thrombocytopenia (Ai et al., 2014 review).
Liver Transaminases (ALT, AST) ALT $7\text{–}56\text{ U/L}$; AST $8\text{–}33\text{ U/L}$ (standard reference range) Safety check Trial exclusion threshold is ALT or AST $> 2.5\times$ ULN (NCT03455205); screens for herbal adulterant or pesticide hepatotoxicity.
Coagulation Panel (PT / INR) INR $0.8\text{–}1.1$ (standard reference range) Safety check Monitors for prolonged clotting time from platelet/coagulation inhibition (Das et al., 2019), especially if co-administered with antithrombotics.
Total Prostate-Specific Antigen (PSA) $0.0\text{–}4.0\text{ ng/mL}$ (standard reference range) Safety check Monitored in men due to preclinical AR upregulation by Codonopsis Radix (Zhang et al., 2021); drawn after 48 hours without ejaculation.
  • Physical performance: Objective functional tracking uses 6MWD, handgrip strength, and five-time chair stand speed at baseline and week 12 (Hua et al., 2026).
  • Vitality and breathing: Subjective logs track daily fatigue, post-exercise recovery, and exertional breathlessness.
  • Digestive and hemostatic tolerance: Tolerance tracking records stool consistency, appetite, and any unexplained bruising.

Emerging Research

  • Standalone Codonopsis pilosula oral liquid for cancer-related fatigue: NCT05613465 is a double-blind RCT ($N = 100$, scheduled completion 2024 passed, status unknown, no results posted) testing oral Codonopsis pilosula versus placebo during pancreatic cancer chemotherapy. Positive results would provide the first standalone human RCT efficacy data; null results would reinforce multi-herb dependence.
  • Multicenter COPD prevention in high-risk adults: NCT06375824 is a 24-month double-blind RCT ($N = 1,100$, not yet recruiting) testing Bufei Recipe (containing Codonopsis pilosula and Astragalus) in Preserved Ratio Impaired Spirometry (reduced lung volume with normal airflow ratio). Positive results would validate early respiratory prevention; null findings would limit use to established COPD.
  • Tumor immune microenvironment remodeling with checkpoint blockade: NCT07843251 is a Phase 4 trial ($N = 30$, not yet recruiting) combining neoadjuvant SFI with programmed cell death protein 1 (PD-1, an immune checkpoint receptor) inhibitors in lung cancer. Positive pathological response data would support immunotherapy synergy; null data would weaken integrative oncology claims.
  • Double-blind gastrointestinal cancer fatigue trial: NCT03455205 ($N = 270$, scheduled completion 2019 passed, status unknown, no results posted) evaluated intravenous SFI (500 mL/day) versus saline placebo on Piper Fatigue Scale scores during chemotherapy. Publication of positive results would strengthen fatigue claims, whereas unpublished null results suggest publication bias in prior unblinded trials.
  • Separating pro-longevity fractions from androgenic constituents: Preclinical studies demonstrating FOXO-dependent locomotor healthspan gains from luteolin and glycitein (Zhuang et al., 2026) and gut-brain longevity-related effects from purified CPPs (Wan et al., 2026) contrast with prostate AR stimulation by crude root extracts (Zhang et al., 2021).

Conclusion

Dang Shen (Codonopsis pilosula, Codonopsis pilosula var. modesta, and Codonopsis tangshen) is a classical East Asian tonic root whose complex sugars and aromatic plant compounds influence cellular energy metabolism, antioxidant defenses, immune cell signaling, and gut-brain barrier integrity. Across human clinical trials, multi-herb oral formulations and intravenous co-extracts containing Dang Shen show supportive benefits for lung function and walking distance in chronic lung disease, muscle mass and strength in older adults with diabetes-related muscle loss, memory performance when paired with Ginkgo biloba, and blood-count and nerve protection during chemotherapy.

However, the human evidence base carries a fundamental limitation for proactive longevity use: published randomized trials test Dang Shen within multi-herb formulas or manufacturer-sponsored injections rather than as a standalone oral root extract, and many cancer-care and heart-failure studies are unblinded single-center trials. Furthermore, a controlled trial in lung scarring preserved total lung air volume without improving forcefully exhaled air volume, showing that multi-herb effects are condition-specific.

While Dang Shen shows mild digestive tolerability in clinical studies, animal and cell findings identify important biological trade-offs, including stimulation of male hormone receptors in the prostate that counteracts prostate cancer therapy, inhibition of liver drug-metabolizing enzymes, slowed blood clotting, and commercial contamination with sulfur dioxide bleach, agricultural pesticides, heavy metals, or substitute roots. Consequently, the evidence supports a conditional profile centered on verified, sulfur-free extracts in populations without hormone-sensitive prostate disease or bleeding risks.

Top - Benefits - Risks - Protocol